Objective: To assess oncological and ophthalmological outcomes after international referral of uveal melanoma patients for proton therapy. Materials and Methods: This is a retrospective study among Dutch uveal melanoma patients who were treated in Switzerland with 60.0 CGE proton therapy (in 4 fractions) from 1987 to 2019. All patients were ineligible for brachytherapy due to tumour size and/or proximity to the optic nerve. Time-to-event analyses were performed using Kaplan–Meier’s methodology and Cox proportional hazards models. Results: There were 103 patients (104 eyes) with a median largest tumour diameter of 19 mm (range 6–26 mm). Tumours were localised centrally (11%), mid-peripherally (65%) or peripherally (34%). Median follow-up was 7 years. Five-year local control, distant metastasis-free survival and eye preservation rates were 94%, 70% and 81% respectively. At five years, severe, moderate and mild visual impairment was observed in respectively 79%, 4% and 6% of the patients. Larger tumour volumes and more central tumour localisation were associated with severe visual impairment. After correction for these factors, dose to the macula, optic disc and retina, but not optic nerve was significantly associated with severe visual impairment. Conclusion: International referral for proton therapy yielded good tumour control and eye preservation rates, but risk of distant metastasis and severe visual impairment were substantial, possibly due to the selection of advanced tumour stages and/or central localisation. Dose to the macula may be more relevant than dose to the optic nerve for preservation of visual acuity, which is relevant for the treatment planning of proton therapy.
2 January 2024 in Investigative Ophthalmology & Visual Science
Purpose: Although fundus photography is extensively used in ophthalmology, refraction prevents accurate distance measurement on fundus images, as the resulting scaling differs between subjects due to varying ocular anatomy. We propose a PARaxial Optical fundus Scaling (PAROS) method to correct for this variation using commonly available clinical data. Methods: The complete optics of the eye and fundus camera were modeled using ray transfer matrix formalism to obtain fundus image magnification. The subject's ocular geometry was personalized using biometry, spherical equivalent of refraction (RSE), keratometry, and/or corneal topography data. The PAROS method was validated using 41 different eye phantoms and subsequently evaluated in 44 healthy phakic subjects (of whom 11 had phakic intraocular lenses [pIOLs]), 29 pseudophakic subjects, and 21 patients with uveal melanoma. Results: Validation of the PAROS method showed small differences between model and actual image magnification (maximum 3.3%). Relative to the average eye, large differences in fundus magnification were observed, ranging from 0.79 to 1.48. Magnification was strongly inversely related to RSE (R2 = 0.67). In phakic subjects, magnification was directly proportional to axial length (R2 = 0.34). The inverse relation was seen in pIOL (R2 = 0.79) and pseudophakic (R2 = 0.12) subjects. RSE was a strong contributor to magnification differences (1%–83%). As this effect is not considered in the commonly used Bennett–Littmann method, statistically significant differences up to 40% (mean absolute 9%) were observed compared to the PAROS method (P < 0.001). Conclusions: The significant differences in fundus image scaling observed among subjects can be accurately accounted for with the PAROS method, enabling more accurate quantitative assessment of fundus photography.
24 February 2025 in Clinical and Translational Radiation Oncology
Small uveal melanomas are preferably treated with eye-sparing therapies such as brachytherapy or proton beam therapy. Knowledge of clinical outcomes and risk factors is important for personalized patient counselling. Data of all choroidal melanoma patients treated at the Leiden University Medical Center between 2012-2019 with Ruthenium-106 brachytherapy were collected. Time-to-event analyses were performed with the Kaplan-Meier method, risk factors for local failure and visual acuity (VA) decline were identified using Cox proportional hazards models with predefined covariates. 719 patients were included. Median tumour prominence and diameter were 3.8 mm and 11.6 mm, respectively. 52 % of tumours were centrally located, and 19 % were juxtapapillary. Five-year overall survival, eye retention and local failure rates were 83 %, 95 %, and 8 %, respectively. Juxtapapillary location, lower tumour apex doses, and T3-4 tumour stage were significantly associated with local failure. Patients with juxtapapillary tumours had 20 % risk of local failure. Five years posttreatment, 47 % of patients had no functional visual impairment (Snellen VA ≥ 0.5). Lasting functional visual impairment was associated with baseline vision, central tumours, and scleral dose. Patients with central tumours had 75 % risk of mild or worse visual impairment after 5 years. Ruthenium-106 brachytherapy yields good local control and visual outcomes in patients with choroidal melanoma. Juxtapapillary tumours have a high risk of local failure and alternative therapies should be considered in these patients, if available. Patients with central tumours, and those with decreased pre-treatment vision should be counselled on the risk of visual impairment.
Aim: To develop proton beam therapy treatment planning dose constraints for uveal melanoma (UM), more knowledge is needed on the impact of dose on toxicity. Here, we identify risk factors and develop prediction models for lower post-therapeutic visual acuity. Methods: LUMC patients treated at Holland PTC between 2020-2023 (n=135) and at PSI between 1987-2019 (n=100) for UM were included. Candidate predictors for severe and moderate to severe vision impairment (Snellen <0.1 and <0.3) were established through literature review and expert interviews and selected through univariable analysis. Multivariable Cox models were fitted on a randomly selected 2/3 rd of the combined dataset (n=156). Performance of both models was calculated on the training set and on the held-out validation set (n=79). Results: The final models included baseline visual acuity, ciliary body dose and tumour location for both visual acuity cut-offs, supplemented by the optic disk dose and T-stage for visual acuity <0.1 and macula dose for visual acuity <0.3. Internal performance was good (c-indices 0.760 and 0.761 for visual acuity <0.1 and <0.3, respectively). In the held-out validation set, performance was acceptable (c-indices 0.657 and 0.689) and calibration was insufficient for the model predicting visual acuity <0.1, but acceptable for the model predicting visual acuity <0.3. Conclusion: We developed a model predicting moderate to severe visual impairment with good internal performance and acceptable discrimination and calibration on a held-out test set. This is an important step towards NTCP modelling and the development of dose constraints for ocular proton therapy.
About Me
Medical student/ researcher with special focus on oncological and radiotherapeutical research.
Medical student/ researcher with special focus on oncological and radiotherapeutical research.